Adeela Kamal
Executive Vice President & Head of Research & Development Actinium Pharmaceuticals
Dr. Adeela Kamal is Executive Vice President, Head of Research & Development at Actinium Pharmaceuticals, developing targeted radiotherapeutics for cancer patients using the company’s proprietary technology platform. With 25+ years industry experience in Oncology drug discovery and development, she has held key roles at Conforma Therapeutics, Biogen, MedImmune/AstraZeneca, Ferring Pharmaceuticals, and SpringWorks Therapeutics, advancing small molecules and biologics from discovery through clinical development. She holds a B.S. from MIT, a Ph.D. from UT Southwestern, and completed a Howard Hughes post-doctoral fellowship. Adeela will share her expertise in optimizing targeted therapies for cancers with high unmet need.
Seminars
• Targeting the untapped: validation of novel tumor-specific targets for Actinium-225 radiotherapeutics
• Bridging preclinical to clinical: translational studies to optimize efficacy and patient selection
• Addressing high unmet need: Leveraging alpha-emitters to overcome resistance mechanisms
